Cite
HARVARD Citation
Stoch, S. et al. (n.d.). Odanacatib, a selective cathepsin K inhibitor to treat osteoporosis: safety, tolerability, pharmacokinetics and pharmacodynamics – results from single oral dose studies in healthy volunteers. British journal of clinical pharmacology. pp. 1240-1254. [Online].